Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. - Wikidata - wikimedia - TriplyDB

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

http://www.wikidata.org/entity/Q33400078

about

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics New antibody approaches to lymphoma therapy The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Novel Drugs in Follicular Lymphoma Novel CD20 monoclonal antibodies for lymphoma therapy A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.The clinical development of obinutuzumab for the treatment of follicular lymphoma.A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.The role of monoclonal antibodies in the treatment of lymphomas.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.The current status and future impact of targeted therapies in non-Hodgkin lymphoma.The optimal management of follicular lymphoma: an evolving field.How we manage follicular lymphoma.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.Chemotherapy-free treatment in patients with follicular lymphoma.Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.Ofatumumab in the treatment of non-Hodgkin's lymphomas.Breakthrough therapies in B-cell non-Hodgkin lymphoma.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.Targeting indolent non-Hodgkin lymphoma.Rituximab for the treatment of follicular lymphoma.Novel agents in indolent lymphomas.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

P2860

Q26773135-7FF87187-9A35-49DA-A4BF-DC7DE63EB433 Q26782270-B8E32A63-87C2-43F0-88F3-E78B8524B7C3 Q26849243-AE454FA0-056F-4C18-95DD-CEBD02BD18DB Q27022373-6AFAC40E-DCBA-42F8-9F5F-50042320E628 Q28072397-457B5AAF-D218-4E90-893C-FE2958D8FF5C Q28076335-6FF2BF43-2924-4135-B39D-FC25637A9BA3 Q28390112-2D0CB0AC-F3C3-49D8-88AA-4F41F7F9F49B Q33410306-BE26F462-B675-4457-82C8-192555181E99 Q33565265-7BFADD6B-46AC-49D1-A148-0C54DB7ABEB0 Q33626106-12FC252F-E1B3-4B59-BFDF-D6D20AAEF06F Q34725757-38F504B7-13C7-423E-B215-330B6738AA81 Q35040896-6161DC02-E24D-47CD-9D3D-1D5E3EDB4CFB Q35142620-17C863BC-4FEA-4962-A68B-1ED6105A8B59 Q36979140-F3D70301-3EC4-4562-A281-9D204EC676EC Q37046984-289FECA3-964E-4DC2-B744-3144744E28F4 Q37118955-00E2D650-216A-49B5-B63D-EAD4303B36DD Q37178611-C49BB3CD-50AA-4933-93A4-4F8451E54661 Q37524930-B595BB07-CDDF-4C6A-BF0D-86D70F4E9420 Q38029382-07C6124C-898E-4ADA-9923-1D67B67E2A40 Q38069595-FB63BE90-CA1D-4C54-A041-EBB042E139B2 Q38088002-151575BF-93F4-4463-A223-912AD73AEE00 Q38095123-3E1A2382-173D-414F-8178-EBDFC22E7CA6 Q38124009-BE78F315-B4C1-4907-B5B5-E64A133A9EEB Q38191811-E6395718-AD44-4DFE-BD29-0E738EF00713 Q38204975-0A84629C-85D4-4641-9CD4-068D310EB481 Q38273851-FF141F0D-5E3F-4111-96FB-F4642ED450FA Q38317235-DEE71EBB-6B42-4D57-B577-E3D4380D5758 Q38417140-12C99EC5-470C-4A4F-9CB9-58805F0ADDFC Q38434473-E6D9A85E-7995-4D4C-9258-68D625789249 Q38516077-1E21CE3A-2F67-4A1B-AF60-5647BE339AEA Q38708600-BD4823E0-14AC-4F90-8EB3-B06BD02E2A15 Q38787141-E18C0A06-C8AB-4544-BC9D-27BA1A1ABC74 Q38876219-B5F1E3AA-D3CB-4185-89A5-0B64FF5F5E02 Q38896113-88FCAEAD-0062-4C89-9A7E-4DFBFE7A301A Q38916526-22A70325-3186-42C7-8963-8C8E95BD716E Q38917848-F2B28EE1-4164-4A27-91BE-8CA5B923710D Q39360775-AE02500D-A46D-43D0-9CC7-47D511832D91 Q39431412-1963A251-E5E3-42CB-AD7A-A0E363359910 Q41387926-5E25AD41-EA81-4488-944B-C9F551A490A9 Q41966195-51E9EF77-DC0A-4E7D-A3AC-AB78002770CF

P2860

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

http://www.wikidata.org/entity/Q33400078

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Ofatumumab monotherapy in ritu ...... ults from a multicenter study.

@ast

Ofatumumab monotherapy in ritu ...... ults from a multicenter study.

@en

type

label

Ofatumumab monotherapy in ritu ...... ults from a multicenter study.

@ast

Ofatumumab monotherapy in ritu ...... ults from a multicenter study.

@en

prefLabel

Ofatumumab monotherapy in ritu ...... ults from a multicenter study.

@ast

Ofatumumab monotherapy in ritu ...... ults from a multicenter study.

@en

P1433

Q33400078-CD168875-43D9-41D0-910E-90CDDFE109BF

P1476

Q33400078-574295B8-7E6C-4FD9-A4FF-F0C427346F71

P2093

Q33400078-05F6E258-EEF3-41D8-9B8C-482222C29FEC

Q33400078-11277315-8F25-4654-91D8-DC266E752639

Q33400078-1160A09A-377D-4F5B-8BBA-02431BAB1C0E

Q33400078-58CF9462-0C69-4799-B2F4-575AA33411E0

Q33400078-67263A34-8214-4D1B-88AA-1410DDA9B71C

Q33400078-6B81E629-6AE4-41BD-8E02-12DE496CA492

Q33400078-7B9BD55F-0E2A-4BAD-8BC2-75FF0B2CDA7B

Q33400078-7D70BF56-A844-44AA-AACC-9608C7B83AC9

Q33400078-7D87C3C0-A828-493D-9B7D-8CBCE5083EF3

Q33400078-995CF09F-02C1-42EE-BA8A-3758229A811B

P304

Q33400078-11F8FE2B-22B8-4ED6-AEF4-2357A22843D9

P31

Q33400078-2DB0884F-6896-494E-8D3A-953F43748C89

P356

Q33400078-D1E89976-8948-4FB2-8795-E317D89D1E19

P407

Q33400078-6A49F87A-F89D-4692-90AC-7266B7BE6A24

P433

Q33400078-2755665B-0E44-4324-8D83-45FF89D37263

P478

Q33400078-DE6B921A-FF1B-461C-8A38-C77DE8377063

P50

Q33400078-4625AFDF-2B8C-4D26-925E-83FF5358138B

Q33400078-5EDEF498-F15B-4E6E-A289-BA15837C37D8

Q33400078-7A2C80BC-645A-4B13-AD13-4068A5DA4DD3

Q33400078-CC692DBA-1724-4533-A323-7F04DCC6F8E0

P577

Q33400078-2A0B0F7A-F31D-482F-8767-0FA7E365386F

P5875

Q33400078-54E5F12E-80D6-494A-AA53-DF6D2A46C0E7

P698

Q33400078-B4B5481E-B782-4436-B530-178BF9102A18

P921

Q33400078-BE1E976C-6845-4AD3-A7FF-45A02A72188F

P356

BLOOD-2011-09-378323

P1433

P1476

Ofatumumab monotherapy in ritu ...... sults from a multicenter study

@en

P2093

405 Study Investigators

http://www.w3.org/2001/XMLSchema#string

Andrzej Hellmann

http://www.w3.org/2001/XMLSchema#string

Anton Hagenbeek

http://www.w3.org/2001/XMLSchema#string

Charlotte A Russell

http://www.w3.org/2001/XMLSchema#string

Christine G DiRienzo

http://www.w3.org/2001/XMLSchema#string

Eric Jacobsen

http://www.w3.org/2001/XMLSchema#string

Eve Gallop-Evans

http://www.w3.org/2001/XMLSchema#string

Ira Gupta

http://www.w3.org/2001/XMLSchema#string

Kazimierz Kuliczkowski

http://www.w3.org/2001/XMLSchema#string

Lauren Pinter-Brown

http://www.w3.org/2001/XMLSchema#string

P304

3698-3704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-09-378323

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Guillaume Cartron

Vincent Delwail

P577

2012-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221886996

http://www.w3.org/2001/XMLSchema#string

P698

22389254

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial